(NASDAQ: ENVB) Enveric Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.98%.
Enveric Biosciences's earnings in 2024 is -$10,594,461.On average, 2 Wall Street analysts forecast ENVB's earnings for 2024 to be -$17,616,842, with the lowest ENVB earnings forecast at -$18,553,434, and the highest ENVB earnings forecast at -$16,680,250. On average, 2 Wall Street analysts forecast ENVB's earnings for 2025 to be -$9,098,318, with the lowest ENVB earnings forecast at -$12,577,087, and the highest ENVB earnings forecast at -$5,619,550.
In 2026, ENVB is forecast to generate -$6,779,139 in earnings, with the lowest earnings forecast at -$6,779,139 and the highest earnings forecast at -$6,779,139.